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Introduction
The beneficial effects of intensive glycemic control on
reducing the risk of chronic complications in type 1
diabetes were firmly established in the Diabetes Con-
trol and Complications Trial (DCCT).1 The UK Pro-
spective Diabetes Study (UKPDS)2 and a study3 from
Japan showed similar results in type 2 diabetes. Both
continuous subcutaneous insulin infusion (CSII) and
multiple daily injection (MDI) therapy are effective
means of implementing intensive diabetes management.
A review4 of controlled trials in patients with type 1
diabetes showed that with CSII therapy, the mean
blood glucose concentrations and glycosylated hemo-
globin (HbA1C) values were either slightly lower
than or comparable to those of MDI. In patients with
type 2 diabetes, 2 studies5,6 found that insulin pump
therapy resulted in a marked improvement in blood
glucose concentrations, with a corresponding decrease
in HbA1C levels. At our hospital, insulin pump ther-
apy was introduced in November 2004. We evaluate
its long-term metabolic effects after 3 years of clinical
practice.
Methods
Diabetic patients treated with insulin pump therapy
between November 2004 and October 2007 in our
diabetes clinic were retrospectively enrolled. Patients
treated for less than 1 year or subjects who had used
pump therapy during pregnancy were excluded. Body
weight, total daily insulin dose, duration of diabetes,
and the reasons for pump therapy were recorded at the
start of therapy. Patients were observed for possible
complications during pump therapy, such as adverse
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reactions at the infusion site, hypoglycemia, and dia-
betic ketoacidosis. The total daily dose of infused insulin
during the 3 days before the end of the study was re-
corded for each patient. The last known HbA1C
value prior to the initiation of CSII therapy was used
as the baseline value. Subsequent HbA1C values were
collected at 12-week intervals.
Statistical data analyses were performed using SPSS
version 12.0 (SPSS Inc., Chicago, IL, USA). Descriptive
statistics were used to describe the cohort. The differ-
ences in body weight and required daily insulin dose
per kilogram of body weight between baseline and the
end of the study were compared using the paired t test.
One-way ANOVA and post hoc multiple comparisons
with the least significant difference method were used
to compare baseline HbA1C values with the follow-up
data. Statistical significance was defined as p < 0.05.
Results
Between November 2004 and October 2007, 26 dia-
betic patients were treated with insulin pump therapy
at our diabetes clinic. Five of the patients were treated
only during pregnancy. At the time of data collection,
16 patients had been treated continuously for at least
1 year. Of them, 3 became pregnant and 1 was lost to
follow-up. After excluding these 4 cases, the 12 remain-
ing cases had continued with CSII therapy up to the
time of data collection, with mean treatment duration
of 2.3 years. The clinical characteristics of the patients
are shown in Table 1. Twelve patients (7 females, 5
males) were included in the study. Their mean age at
the start of pump therapy was 41.6 years (range, 25–76
years), and mean duration of diabetes was 13.6 years.
Prior to CSII therapy, mean insulin requirement was
46.4±15.0U/day, corresponding to 0.77±0.22U/kg
body weight/day. Seven patients had been on twice-
daily injections of premix insulin, and 5 had been on
MDI therapy. The reasons for starting pump therapy
were to optimize metabolic control in 10 (83%) patients,
to enable a more flexible lifestyle in 8 (67%) patients,
to reduce fluctuation of blood glucose in 3 (25%),
and to prevent severe hypoglycemia in 1 (8.3%). All
patients had ≥ 2 indications for starting pump therapy.
HbA1C values improved significantly after beginning
CSII therapy (Figure 1), decreasing from 8.7 ± 1.3%
at initiation to 7.2 ± 0.6% at 3 months and 7.4 ± 1.1%
at 6 months of therapy. The reduced level was main-
tained at 1, 2 and 3 years of therapy (HbA1C values
were 7.0%, 6.7% and 6.6%, respectively; p < 0.05 vs.
baseline).
Mean body weight did not change significantly from
the start to the end of the study (60.2 vs. 61.4 kg). The
required insulin dose was 0.77±0.22U/kg/day before
CSII and 0.72±0.28U/kg/day at the end of the study;
the difference was also not statistically significant.
Whereas 1 patient experienced several episodes of
severe hypoglycemia (defined as an episode with symp-
toms consistent with hypoglycemia in which the patient
requires the assistance of another person and which is
associated with prompt recovery after oral carbohy-
drate or intravenous glucose) with subcutaneous insulin
injection therapy twice daily, severe hypoglycemia did
not develop in any of the patients during CSII therapy.
Diabetic ketoacidosis likewise did not occur in any
patient throughout the entire duration of CSII therapy.
Only 1 patient reported infusion site infection during
pump therapy, which resolved with the application of
topical antibiotic. He did not report any adverse injec-
tion site reaction (redness or soreness) during the course
of intermittent subcutaneous insulin injection therapy.
Discussion
In the 12 patients, HbA1C improved from a mean
baseline value of 8.7 ± 1.3% to 7.0%, 6.7% and 6.6% at
1, 2 and 3 years of CSII therapy, respectively. Some
studies7,8 have shown the benefit of lowering blood
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Table 1. Clinical characteristics of the 12 patients on insulin pump therapy*
Characteristics Type 1 DM Type 2 DM Total
Gender (male/female) 2/4 3/3 5/7
Age at start of pump use (yr) 31.5 ± 5.3 (25–40) 51.7 ± 14.8 (35–76) 41.6 ± 15.0 (25–76)
Duration of diabetes at start of 15.7 ± 8.2 (7–29) 11.5 ± 4.3 (5–18) 13.6 ± 6.6 (5–29)
pump use (yr)
HbA1C before start of pump use 8.8 ± 1.4 (6.8–10.8) 8.6 ± 1.4 (6.8–10.7) 8.7 ± 1.3 (6.8–10.8)
Daily insulin dose before start of 0.79 ± 0.24 (0.52–1.12) 0.79 ± 0.25 (0.55–1.20) 0.77 ± 0.22 (0.52–1.20)
pump use (U/kg/d)
Duration of pump therapy (yr) 2.9 ± 0.1 (2.7–3.0) 1.7 ± 0.7 (1.0–2.7) 2.3 ± 0.8 (1.0–3.0)
*Data presented as n or mean ± standard deviation (range). DM = diabetes mellitus; HbA1C = glycosylated hemoglobin.
glucose level with pump therapy regardless of the type
of diabetes mellitus and the age of the subject. At the
end of our study, mean body weight had not changed
significantly, implying that calorific intake remained
consistent during the study period. Since mean body
weight and the average daily dose of insulin per kilo-
gram of body weight did not change significantly after
CSII therapy, the reduction in HbA1C level may indi-
cate improved insulin sensitivity with the use of contin-
uous insulin infusion. While some investigators reported
a deterioration in metabolic control after 6 months of
CSII therapy,9 some studies demonstrated that the
initial lowering of HbA1C with CSII was sustainable
for more than 1 year.10–12 This was corroborated by
our subjects, who demonstrated significant improve-
ments in HbA1C levels that were sustained for 3 years
after switching from conventional intermittent insulin
injection to CSII therapy.
In our study, a 76-year-old patient was poorly con-
trolled with MDI therapy. After insulin pump therapy,
her HbA1C improved significantly. Other case studies
have also shown the feasibility of insulin pump therapy
in elderly patients with type 1 diabetes mellitus.13,14
For optimal results, it is important that patients in this
age group be selected carefully for pump therapy, edu-
cated thoroughly, and followed diligently by a team of
trained professionals.
The improved glucose control in our CSII-treated
patients might have been the result of several factors.
Besides tailoring insulin delivery to an individual’s re-
quirement on a 24-hour basis, factors other than the
pump technology itself could also have contributed to
the improvement. The availability of a multidisciplinary
diabetes care team with the required skills and experi-
ence in pump therapy is critically important.15,16 Long-
term support and guidance should also be available to
address questions and promptly resolve problems
unique to special circumstances.17 Proper selection of
candidates for pump therapy is also vitally important.
They need to be familiar with various aspects of self-
care and to maintain close contact with members of the
diabetes care team. In addition, they have to be taught
carbohydrate counting and other practical issues, in-
cluding insulin replenishment, timely replacement of
tubing, proper care of the needle insertion site, and
procedures to follow in case of pump malfunction. They
should also be instructed to watch for potential prob-
lems during pump therapy, such as inadvertent inter-
ruption of insulin delivery and irritation or infection
at the needle insertion site.
For 10 of our patients, pump therapy was initiated
after a few hours of instruction in the ambulatory 
setting. Two subjects began pump therapy during a
week-long hospitalization. One might argue that the
improved control during pump therapy might partly
be due to the more extensive instructions that resulted
in more educated patients. However, several controlled
trials investigating the effect of education in type 1 dia-
betes patients failed to show improvement in glycemic
control through education alone.18,19
No severe hypoglycemia or diabetic ketoacidosis
occurred in our patients during the study period. Al-
though earlier studies20,21 showed increased rates of se-
vere hypoglycemia and diabetic ketoacidosis with pump
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Figure 1. Glycosylated hemoglobin (HbA1C) levels before and after insulin pump therapy (all subsequent HbA1C values were significantly
decreased compared to baseline, p < 0.05).
therapy, some newer studies22,23 showed decreased
risks of these complications. This improvement may
be attributed to improved diabetes education, self care,
and improved pump technology.24 For our patients,
we gave thorough instructions on the prevention of
severe hypoglycemia and diabetic ketoacidosis.
Our study was a retrospective analysis, which ex-
cluded 14 of the 26 treated patients from the cohort
for various reasons. The omission of those data might
have introduced confounders and bias into the study.
Since pregnancy was the main reason for most of the
excluded patients, their inclusion would have shown
even better glycemic control with pump therapy.25,26
Second, both types of diabetes were represented
equally in our study. The results may therefore not
apply to the predominantly type 2 diabetes mellitus
population as a whole. By adding future data to our
preliminary experience, we trust that a more clear-cut
picture will eventually emerge.
In conclusion, our experience has shown that
insulin pump treatment results in a significant reduc-
tion in HbA1C (by more than 1%) that is sustainable
for at least 3 years. Pump therapy may therefore be
warranted when intermittent insulin injection fails to
achieve treatment goals.
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